Abstract： Objective： To investigate the effect of compound Qishao Jiangya tablets on JAK/STAT signal pathway mediated by angiotensin Ⅱ type 1 receptor AT1 in spontaneously hypertensive rats with left ventricular hypertrophy. Methods：11 week old spontaneously hypertensive rats were randomly divided into model group，compound Qishao Jiangya tablets group and valsartan group. Wistar Kyoto rats(WKY) with normal blood pressure were used as the control group，with 15 rats in each group. The blood pressure，plasma angiotensin Ⅱ(Ang Ⅱ) concentration，AT1 mRNA expression and JAK/ STAT signal pathway related protein expression were observed before and after treatment. Results：There was no significant difference in systolic blood pressure between model group， compound Qishao Jiangya tablets group and valsartan group before administration(P＞0.05). After administration，the systolic blood pressure of compound Qishao Jiangya tablets group and valsartan treatment group decreased compared with that before treatment， and there was significant difference compared with model group(P＜0.01). After administration，there was no significant difference between compound Qishao Jiangya tablet group and valsartan group at the same time point(P＞0.05). Compared with the control group，the plasma Ang Ⅱ level and myocardial AT1 mRNA in the model group were significantly higher(P＜0.01). The levels of plasma Ang Ⅱ and myocardial AT1 mRNA in compound Qishao Jiangya tablets group and valsartan group were significantly lower than those in model group(P＜0.01). There was no significant difference between compound Qishao Jiangya tablet group and valsartan group(P＞0.05). Janus kinase(JAK1)， signal transducer and activator(STAT3) and cysteine aspartate specific protease- 3 (Caspase- 3) were highly expressed in the model group， and the expression of JAK1， STAT3 and Caspase- 3 in the compound Qishao Jiangya tablets group and valsartan treatment group decreased. Compared with the model group， the difference was statistically significant(P＜0.05， P＜0.01). Conclusion： Compound Qishao Jiangya tablets may inhibit cardiomyocyte apoptosis and reverse hypertensive left ventricular hypertrophy by acting on JAK/STAT signal pathway related proteins mediated by AT1.